Therapy for Apnoea of Prematurity: A Retrospective Study on Effects of Standard Dose and Genetic Variability on Clinical Response to Caffeine Citrate in Chinese Preterm Infants.

Szczegóły
Abstrakt

Tytuł:: Therapy for Apnoea of Prematurity: A Retrospective Study on Effects of Standard Dose and Genetic Variability on Clinical Response to Caffeine Citrate in Chinese Preterm Infants.
Autorzy:: He X; Department of Pharmacy, Children's Hospital of Nanjing Medical University, Nanjing, China.
Qiu JC; Department of Pharmacy, Children's Hospital of Nanjing Medical University, Nanjing, China.
Lu KY; Neonatal Intensive Care Unit, Children's Hospital of Nanjing Medical University, Nanjing, China.
Guo HL; Department of Pharmacy, Children's Hospital of Nanjing Medical University, Nanjing, China.
Li L; School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, China.
Jia WW; State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Ni MM; Department of Pharmacy, Children's Hospital of Nanjing Medical University, Nanjing, China.
Liu Y; Neonatal Intensive Care Unit, Children's Hospital of Nanjing Medical University, Nanjing, China.
Xu J; Department of Pharmacy, Children's Hospital of Nanjing Medical University, Nanjing, China.
Chen F; Department of Pharmacy, Children's Hospital of Nanjing Medical University, Nanjing, China. .
Cheng R; Neonatal Intensive Care Unit, Children's Hospital of Nanjing Medical University, Nanjing, China. .
Źródło:: Advances in therapy [Adv Ther] 2021 Jan; Vol. 38 (1), pp. 607-626. Date of Electronic Publication: 2020 Nov 12.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Publication: New York : Springer Healthcare Communications, 2008- : Health Communications Inc.
Original Publication: Metuchen, N.J. : Health Communications Inc., c1984-
MeSH Terms:: Apnea*/drug therapy
Apnea*/genetics
Caffeine*/therapeutic use
China ; Citrates ; Humans ; Infant ; Infant, Newborn ; Infant, Premature ; Reference Standards ; Retrospective Studies
References:: Eichenwald EC, F. Committee on A.A.o.P. Newborn, apnea of prematurity. Pediatrics. 2016;137(1):e20153757. (PMID: 10.1542/peds.2015-3757)
Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, Solimano A, Tin W, G. Caffeine for Apnea of Prematurity Trial. Caffeine therapy for apnea of prematurity. N Engl J Med. 2006;354(20):2112–21. (PMID: 10.1056/NEJMoa054065)
Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, Solimano A, Tin W, G. Caffeine for Apnea of Prematurity Trial. Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med. 2007;357(19):1893–902. (PMID: 10.1056/NEJMoa073679)
Schmidt B, Anderson PJ, Doyle LW, Dewey D, Grunau RE, Asztalos EV, Davis PG, Tin W, Moddemann D, Solimano A, Ohlsson A, Barrington KJ, Roberts RS, I. Caffeine for Apnea of Prematurity Trial. Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. JAMA. 2012;307(3):275–82. (PMID: 10.1001/jama.2011.2024)
Schmidt B, Roberts RS, Anderson PJ, Asztalos EV, Costantini L, Davis PG, Dewey D, D’Ilario J, Doyle LW, Grunau RE, Moddemann D, Nelson H, Ohlsson A, Solimano A, Tin W, G. Caffeine for Apnea of Prematurity Trial. Academic performance, motor function, and behavior 11 years after neonatal caffeine citrate therapy for apnea of prematurity: an 11-year follow-up of the CAP randomized clinical trial. JAMA Pediatr. 2017;171(6):564–72. (PMID: 10.1001/jamapediatrics.2017.0238)
Murner-Lavanchy IM, Doyle LW, Schmidt B, Roberts RS, Asztalos EV, Costantini L, Davis PG, Dewey D, D'Ilario J, Grunau RE, Moddemann D, Nelson H, Ohlsson A, Solimano A, Tin W, Anderson PJ, G. Caffeine for Apnea of Prematurity Trial. Neurobehavioral outcomes 11 years after neonatal caffeine therapy for apnea of prematurity. Pediatrics. 2018;141(5):e20174047. (PMID: 10.1542/peds.2017-4047)
Lodha A, Entz R, Synnes A, Creighton D, Yusuf K, Lapointe A, Yang J, Shah PS, N. investigators of the Canadian Neonatal, N. the Canadian Neonatal Follow-up. Early caffeine administration and neurodevelopmental outcomes in preterm infants. Pediatrics. 2019;143(1):e20181348. (PMID: 10.1542/peds.2018-1348)
Lodha A, Seshia M, McMillan DD, Barrington K, Yang J, Lee SK, Shah PS, N. Canadian Neonatal. Association of early caffeine administration and neonatal outcomes in very preterm neonates. JAMA Pediatr. 2015;169(1):33–8. (PMID: 10.1001/jamapediatrics.2014.2223)
Bloch-Salisbury E, Hall MH, Sharma P, Boyd T, Bednarek F, Paydarfar D. Heritability of apnea of prematurity: a retrospective twin study. Pediatrics. 2010;126(4):e779–87. (PMID: 10.1542/peds.2010-0084)
Kumral A, Tuzun F, Yesilirmak DC, Duman N, Ozkan H. Genetic basis of apnoea of prematurity and caffeine treatment response: role of adenosine receptor polymorphisms: genetic basis of apnoea of prematurity. Acta Paediatr. 2012;101(7):e299-303. (PMID: 10.1111/j.1651-2227.2012.02664.x)
Mohammed S, Nour I, Shabaan AE, Shouman B, Abdel-Hady H, Nasef N. High versus low-dose caffeine for apnea of prematurity: a randomized controlled trial. Eur J Pediatr. 2015;174(7):949–56. (PMID: 10.1007/s00431-015-2494-8)
Koch G, Datta AN, Jost K, Schulzke SM, van den Anker J, Pfister M. Caffeine citrate dosing adjustments to assure stable caffeine concentrations in preterm neonates. J Pediatr. 2017;191:50–6 ((e1)). (PMID: 10.1016/j.jpeds.2017.08.064)
F. Committee on, Newborn P. American Academy of, Apnea, sudden infant death syndrome, and home monitoring. Pediatrics. 2003;111(4 Pt 1):914–7.
Lodha A, Zhu Q, Lee SK, Shah PS, N. Canadian Neonatal. Neonatal outcomes of preterm infants in breech presentation according to mode of birth in Canadian NICUs. Postgrad Med J. 2011;87(1025):175–9. (PMID: 10.1136/pgmj.2010.107532)
Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1500 gm. J Pediatr. 1978;92(4):529–34. (PMID: 10.1016/S0022-3476(78)80282-0)
Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. Pediatr Clin N Am. 1986;33(1):179–201. (PMID: 10.1016/S0031-3955(16)34975-6)
Chen F, Hu ZY, Parker RB, Laizure SC. Measurement of caffeine and its three primary metabolites in human plasma by HPLC-ESI-MS/MS and clinical application. Biomed Chromatogr. 2017; 31(6). https://doi.org/10.1002/bmc.3900 .
Jia W, Li J, Du F, Sun Y, Xu F, Wang F, Olaleye OE, Chen D, Tang W, Zuo J, Li C. Assay development for determination of DZ2002, a new reversible SAHH inhibitor, and its acid metabolite DZA in blood and application to rat pharmacokinetic study. J Pharm Anal. 2019;9(1):25–33. (PMID: 10.1016/j.jpha.2018.09.001)
Taha D, Kirkby S, Nawab U, Dysart KC, Genen L, Greenspan JS, Aghai ZH. Early caffeine therapy for prevention of bronchopulmonary dysplasia in preterm infants. J Matern Fetal Neonatal Med. 2014;27(16):1698–702. (PMID: 10.3109/14767058.2014.885941)
Guthrie SO, Gordon PV, Thomas V, Thorp JA, Peabody J, Clark RH. Necrotizing enterocolitis among neonates in the United States. J Perinatol. 2003;23(4):278–85. (PMID: 10.1038/sj.jp.7210892)
Cox C, Hashem NG, Tebbs J, Bookstaver PB, Iskersky V. Evaluation of caffeine and the development of necrotizing enterocolitis. J Neonatal Perinatal Med. 2015;8(4):339–47. (PMID: 10.3233/NPM-15814059)
Lampkin SJ, Turner AM, Lakshminrusimha S, Mathew B, Brown J, Fominaya CE, Johnson KK. Association between caffeine citrate exposure and necrotizing enterocolitis in preterm infants. Am J Health Syst Pharm. 2013;70(7):603–8. (PMID: 10.2146/ajhp120457)
Shrestha B, Jawa G. Caffeine citrate––Is it a silver bullet in neonatology? Pediatr Neonatol. 2017;58(5):391–7. (PMID: 10.1016/j.pedneo.2016.10.003)
Natarajan G, Botica ML, Thomas R, Aranda JV. Therapeutic drug monitoring for caffeine in preterm neonates: an unnecessary exercise? Pediatrics. 2007;119(5):936–40. (PMID: 10.1542/peds.2006-2986)
Puia-Dumitrescu M, Smith PB, Zhao J, Soriano A, Payne EH, Harper B, Bendel-Stenzel E, Moya F, Chhabra R, Ku L, Laughon M, Wade KC, C. Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering. Dosing and safety of off-label use of caffeine citrate in premature infants. J Pediatr. 2019;211:27–32 ((e1)). (PMID: 10.1016/j.jpeds.2019.04.028)
Thorn CF, Aklillu E, McDonagh EM, Klein TE, Altman RB. PharmGKB summary: caffeine pathway. Pharmacogenet Genomics. 2012;22(5):389–95. (PMID: 222935363381939)
Song G, Sun X, Hines RN, McCarver DG, Lake BG, Osimitz TG, Creek MR, Clewell HJ, Yoon M. Determination of human hepatic CYP2C8 and CYP1A2 age-dependent expression to support human health risk assessment for early ages. Drug Metab Dispos. 2017;45(5):468–75. (PMID: 10.1124/dmd.116.074583)
McLellan TM, Caldwell JA, Lieberman HR. A review of caffeine’s effects on cognitive, physical and occupational performance. Neurosci Biobehav Rev. 2016;71:294–312. (PMID: 10.1016/j.neubiorev.2016.09.001)
Kumar VHS, Lipshultz SE. Caffeine and clinical outcomes in premature neonates. Children (Basel). 2019;6(11):118.
Borea PA, Gessi S, Merighi S, Vincenzi F, Varani K. Pharmacology of adenosine receptors: the state of the art. Physiol Rev. 2018;98(3):1591–625. (PMID: 10.1152/physrev.00049.2017)
Chen JF, Eltzschig HK, Fredholm BB. Adenosine receptors as drug targets–what are the challenges? Nat Rev Drug Discov. 2013;12(4):265–86. (PMID: 10.1038/nrd3955)
Nordestgaard AT, Nordestgaard BG. Coffee intake, cardiovascular disease and all-cause mortality: observational and Mendelian randomization analyses in 95,000–223,000 individuals. Int J Epidemiol. 2016;45(6):1938–52. (PMID: 28031317)
Josse AR, Da Costa LA, Campos H, El-Sohemy A. Associations between polymorphisms in the AHR and CYP1A1-CYP1A2 gene regions and habitual caffeine consumption. Am J Clin Nutr. 2012;96(3):665–71. (PMID: 10.3945/ajcn.112.038794)
Ziv-Gal A, Flaws JA, Mahoney MM, Miller SR, Zacur HA, Gallicchio L. Genetic polymorphisms in the aryl hydrocarbon receptor-signaling pathway and sleep disturbances in middle-aged women. Sleep Med. 2013;14(9):883–7. (PMID: 10.1016/j.sleep.2013.04.007)
Shivanna B, Maity S, Zhang S, Patel A, Jiang W, Wang L, Welty SE, Belmont J, Coarfa C, Moorthy B. Gene expression profiling identifies cell proliferation and inflammation as the predominant pathways regulated by aryl hydrocarbon receptor in primary human fetal lung cells exposed to hyperoxia. Toxicol Sci. 2016;152(1):155–68. (PMID: 10.1093/toxsci/kfw071)
Sauzeau V, Carvajal-Gonzalez JM, Riolobos AS, Sevilla MA, Menacho-Marquez M, Roman AC, Abad A, Montero MJ, Fernandez-Salguero P, Bustelo XR. Transcriptional factor aryl hydrocarbon receptor (Ahr) controls cardiovascular and respiratory functions by regulating the expression of the Vav3 proto-oncogene. J Biol Chem. 2011;286(4):2896–909. (PMID: 10.1074/jbc.M110.187534)
Retey JV, Adam M, Honegger E, Khatami R, Luhmann UF, Jung HH, Berger W, Landolt HP. A functional genetic variation of adenosine deaminase affects the duration and intensity of deep sleep in humans. Proc Natl Acad Sci USA. 2005;102(43):15676–81. (PMID: 10.1073/pnas.0505414102)
Mazzotti DR, Guindalini C, Pellegrino R, Barrueco KF, Santos-Silva R, Bittencourt LR, Tufik S. Effects of the adenosine deaminase polymorphism and caffeine intake on sleep parameters in a large population sample. Sleep. 2011;34(3):399–402. (PMID: 10.1093/sleep/34.3.399)
Contributed Indexing:: Keywords: AHR; AOP; Adenosine receptors; CYP1A2; Caffeine; Phosphodiesterase; Polymorphism; Therapeutic drug monitoring
Substance Nomenclature:: 0 (Citrates)
3G6A5W338E (Caffeine)
U26EO4675Q (caffeine citrate)
Entry Date(s):: Date Created: 20201112 Date Completed: 20210414 Latest Revision: 20210414
Update Code:: 20240105
DOI:: 10.1007/s12325-020-01544-2
PMID:: 33180318
: Czasopismo naukowe

Full Text Finder

Introduction: Apnoea of prematurity (AOP) is among the most common diagnoses in the neonatal intensive care unit. Caffeine treatment is a preferred treatment choice. However, neonatal caffeine therapy results in significant intersubject variability. This study aimed to determine the effects of plasma caffeine levels based on standard dose and genetic variability on clinical response to caffeine citrate in Chinese preterm infants.
Methods: This single-center and retrospective study examined data from 112 preterm infants (< 35 weeks gestational age) between July 2017 and July 2018. Subjects were divided into apnoea-free (n = 48) and apnoeic (n = 64) groups, and their clinical outcomes were summarized. Liquid chromatography-tandem mass spectrometry was used to measure levels of caffeine and its primary metabolites. Eighty-eight single-nucleotide polymorphisms were chosen for genotyping by a MassARRAY system.
Results: Preterm infants in the apnoea-free group were associated with a reduction in the incidence of bronchopulmonary dysplasia and a reduced requirement for patent ductus arteriosus ligation. No significant association was observed between plasma-trough-concentration-to-dose (C 0 /D) ratio and birth weight, gestational age, or postnatal age in either group. Polymorphisms in CYP1A2 and aryl hydrocarbon receptor (AHR) genes did not affect plasma caffeine levels. Polymorphisms in adenosine receptor genes ADORA1 (rs10920568 and rs12744240), ADORA2A (rs34923252 and rs5996696), and ADORA3 (rs10776727 and rs2298191), especially in AHR (rs4410790) and adenosine deaminase (rs521704), play critical roles in the interindividual response to caffeine therapy.
Conclusions: Genetic polymorphisms in caffeine's target receptors, but not the exposure levels based on the standard dosing, were associated with variable responses to caffeine therapy in preterm neonates. Future studies are needed to uncover how these genetic variants affect responses to caffeine therapy in this patient population.

Informacja